DHP is committed to developing novel therapies focused initially on the treatment of four autoimmune and neurodegenerative diseases with unmet medical needs. We have the following clinical trials underway. For eligibility criteria and additional study details, visit www.ClinicalTrials.gov.
Daggerwing Health Pharmaceuticals’ Clinical Programs
| Disease | Study Phase | Trial | Objective | Enrollment Status |
|---|---|---|---|---|
| Systemic Sclerosis | Phase IIa | DHP-101
Double-blind, randomized, intracohort placebo-controlled, multicenter study. |
To evaluate the safety, tolerability, and preliminary efficacy of DHP-101 in patients with diffuse cutaneous systemic sclerosis.
Visit www.systemicsclerosisclinicaltrial.com to learn more about the study. |
Active.
Enrolling in the United States, Australia and New Zealand. |
| Multiple Sclerosis | Initiating Phase IIa | DHP-101
Open label, randomized, multicenter study. |
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DHP-101 in patients with relapsing forms of multiple sclerosis. | Enrollment scheduled to begin early 2023. |
“A clinical trial requires a tremendous amount of time and resources and a collaborative group of professionals working together to find new therapies for people living with devastating diseases. We are now in a Phase IIa clinical trial with our lead product candidate, DHP-101, focused on the potential treatment of the rare disease systemic sclerosis. We would not be where we are today, continuing to advance this investigational study, if it were not for the expert team of investigators, clinical advisors, clinical study teams, ethics committees, and most importantly study participants. Thank you.”
– Joachim P.H. Paul, MD, Dr. med., Chief Medical Officer